Oxalo Therapeutics
Chicago
About Oxalo Therapeutics
Oxalo Therapeutics creates drugs to treat rare kidney diseases and prevent recurring kidney stones. Oxalo Therapeutics is tackling primary hyperoxaluria and other oxalate pathologies. Oxalo Therapeutics develops innovative therapies by leveraging its expertise in the microbiome, translational research, and early-stage technology commercialization. Oxalo's method mimics a natural mechanism for safely removing oxalate from the body, thereby preventing recurrent kidney stones and other oxalate pathologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $3.8M
- Last round: Grant (Apr 2022)
- Website: oxalotherapeutics.com
Industries & Categories
Biotechnology, Clinical Trials, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/oxalo-therapeutics-133653 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.